Annexon (NASDAQ:ANNX) Upgraded by The Goldman Sachs Group to “Hold” Rating

Posted by Geri Gentry on May 13th, 2026

Annexon (NASDAQ:ANNX – Get Free Report) was upgraded by analysts at The Goldman Sachs Group to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a report on Monday, April 20th. Wall Street Zen upgraded shares of Annexon from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Chardan Capital restated a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday, March 20th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.00.

View Our Latest Stock Analysis on ANNX

Annexon Trading Down 4.2%

Shares of Annexon stock opened at $5.44 on Tuesday. The company has a fifty day simple moving average of $5.70 and a 200-day simple moving average of $5.14. Annexon has a 12-month low of $1.67 and a 12-month high of $7.18. The stock has a market cap of $891.29 million, a price-to-earnings ratio of -4.46 and a beta of 1.22.

Annexon (NASDAQ:ANNX – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.07. On average, analysts forecast that Annexon will post -1.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Annexon news, EVP Ted Yednock sold 7,857 shares of Annexon stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total transaction of $40,149.27. Following the transaction, the executive vice president directly owned 97,227 shares of the company’s stock, valued at $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Dean Richard Artis sold 5,290 shares of Annexon stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the transaction, the executive vice president directly owned 123,487 shares in the company, valued at approximately $629,783.70. This trade represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 32,513 shares of company stock valued at $165,973. 12.67% of the stock is currently owned by corporate insiders.

Institutional Trading of Annexon

A number of hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in shares of Annexon by 28.6% during the first quarter. Dimensional Fund Advisors LP now owns 924,078 shares of the company’s stock valued at $5,115,000 after purchasing an additional 205,398 shares during the period. AlphaCentric Advisors LLC bought a new stake in shares of Annexon in the first quarter worth $136,000. Swiss National Bank acquired a new position in Annexon in the first quarter worth $1,307,000. Bank of New York Mellon Corp boosted its holdings in Annexon by 9.2% in the first quarter. Bank of New York Mellon Corp now owns 395,019 shares of the company’s stock worth $2,188,000 after purchasing an additional 33,342 shares during the period. Finally, Fifth Third Bancorp acquired a new position in Annexon in the first quarter worth $196,000.

Key Headlines Impacting Annexon

Here are the key news stories impacting Annexon this week:

Positive Sentiment: HC Wainwright lifted its earnings estimates for Annexon across multiple periods, including FY2026, FY2027, FY2028, and FY2029, signaling improved confidence in the company’s longer-term earnings trajectory.
Positive Sentiment: The firm also raised near-term quarterly EPS forecasts for Q2, Q3, and Q4 2026, which may help reinforce investor sentiment around Annexon’s operating outlook.
Neutral Sentiment: Separate market data showed short interest at zero shares, which does not appear to be a meaningful trading factor in the latest report.
Neutral Sentiment: An awareness-month press release tied to Guillain-Barré syndrome was also published, but it did not include a direct business update or clinical catalyst for Annexon. Article Title

About Annexon

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.